Cervical Cancer Immunology

Cervical Cancer Immunology has gained renewed interest in the last few years. Undoubtedly, the resistant form is widely recognized as a hallmark of critical cancer. Basic research has revealed new objectives that can be modulated with new compounds and methods in the clinical setting. Breast cancer (BC) has been confirmed by recent evidence. Measurement of T-infiltration lymphocytes is suggested as a powerful new tool needed to predict early BC evolution, particularly in HER2-positive and triple-negative subtypes. In addition, T-infiltration lymphocytes, genomic pathways and many other biomarkers in tissue and peripheral blood (e.g. regulatory T-cells and myeloid-derived suppressor cells) are not the only variables to be evaluated. Several current clinical trials are investigating the role of immune checkpoint modulators in both advanced and neo-adjuvant BC therapy.


  • Immunotherapy
  • Immune responce
  • Immunofluorescence
  • Lymph nodes
  • Graft rejection

Related Conference of Cervical Cancer Immunology

October 19-20, 2020

World Congress on Gynecology and Obstetrics

Tokyo, Japan

Cervical Cancer Immunology Conference Speakers

Recommended Sessions

Related Journals

Are you interested in